Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cyclerion Therapeutics (CYCN) stocks in Canada

Learn how to easily invest in Cyclerion Therapeutics stocks.

Cyclerion Therapeutics is a biotechnology business based in the US. Cyclerion Therapeutics stocks (CYCN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.77 – a decrease of 5.34% over the previous week. Cyclerion Therapeutics employs 34 staff and has a trailing 12-month revenue of around $3.5 million.

How to buy shares in Cyclerion Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYCN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cyclerion Therapeutics stock price (NASDAQ:CYCN)

Use our graph to track the performance of CYCN stocks over time.

Cyclerion Therapeutics shares at a glance

Information last updated 2022-01-25.
Latest market close$1.24
52-week range$1.13 - $6.90
50-day moving average $1.85
200-day moving average $2.81
Wall St. target price$10.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cyclerion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cyclerion Therapeutics price performance over time

Historical closes compared with the close of $1.24 from 2022-01-25

1 week (2022-01-20) 2.48%
1 month (2021-12-27) -25.30%
3 months (2021-10-27) -52.49%
6 months (2021-07-27) -61.73%
1 year (2021-01-27) -60.38%
2 years (2020-01-27) -64.77%
3 years (2019-01-23) N/A
5 years (2017-01-23) N/A

Cyclerion Therapeutics financials

Revenue TTM $3.5 million
Gross profit TTM $-46,419,000
Return on assets TTM -34.4%
Return on equity TTM -91.24%
Profit margin 0%
Book value $1.30
Market capitalisation $55.4 million

TTM: trailing 12 months

Cyclerion Therapeutics share dividends

We're not expecting Cyclerion Therapeutics to pay a dividend over the next 12 months.

Cyclerion Therapeutics share price volatility

Over the last 12 months, Cyclerion Therapeutics's shares have ranged in value from as little as $1.13 up to $6.9. A popular way to gauge a stock's volatility is its "beta".

CYCN.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclerion Therapeutics's is 1.6246. This would suggest that Cyclerion Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cyclerion Therapeutics overview

Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. .

Stocks similar to Cyclerion Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

COVID testing stocks

COVID testing stocks

We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.

Read more…


Review the benefits and risks of investing in these tech-focused ETFs.

Read more…
How to buy Canadian blue chip stocks

How to buy Canadian blue chip stocks

Read more…

More guides on Finder

Go to site